Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 346Neoplasms 247Prostatic Neoplasms 198Colorectal Neoplasms 151Lung Neoplasms 130Carcinoma, Non-Small-Cell Lung 108Leukemia, Myeloid, Acute 107Pancreatic Neoplasms 98Multiple Myeloma 89Glioblastoma 77Precursor Cell Lymphoblastic Leukemia-Lymphoma 73Brain Neoplasms 73Head and Neck Neoplasms 72Carcinoma, Hepatocellular 67Squamous Cell Carcinoma of Head and Neck 65Melanoma 62Uterine Cervical Neoplasms 61Ovarian Neoplasms 59Neoplasm Metastasis 55Rectal Neoplasms 52Hematologic Neoplasms 50Recurrence 48Stomach Neoplasms 47Glioma 46Myelodysplastic Syndromes 45Motor Activity 45Triple Negative Breast Neoplasms 44Carcinoma, Renal Cell 44Endometrial Neoplasms 43Sarcoma 41

Interventions

ixabepilone 1Standard of Care 1Practice Guidelines as Topic 1Epothilones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Bilateral Breast Carcinoma × 30 days × Clear all
NCT00877500 2026-05-22

Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
116 enrolled
Breast

Bilateral Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡